# Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia

> **NCT02407470** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Navy General Hospital, Beijing** · enrollment: 90 (estimated)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Rabbit antithymoglobulin (ATG)
- **PROCEDURE:** Adipose derived mesenchymal stem cells ( AD-MSCs)
- **PROCEDURE:** AD-MSC transdifferentiated HSCs (AD-HSCs)

## Key facts

- **NCT ID:** NCT02407470
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407470, "Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02407470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*